Prescription of EPs 7630 is associated with short- and long-term benefits in acute bronchitis: a real-world data analysis

Adrian Gillissen, Thorsten Reineke, Martin Burkart, Petra Funk, Charles Christian Adarkwah, Karel Kostev

Open source

DOI
10.3389/fphar.2025.1652203
Published
2025-09-15
Container
Frontiers in Pharmacology
Publisher
Frontiers Media SA
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fphar.2025.1652203,
  title = {Prescription of EPs 7630 is associated with short- and long-term benefits in acute bronchitis: a real-world data analysis},
  author = {Adrian Gillissen and Thorsten Reineke and Martin Burkart and Petra Funk and Charles Christian Adarkwah and Karel Kostev},
  year = {2025},
  journal = {Frontiers in Pharmacology},
  doi = {10.3389/fphar.2025.1652203},
  url = {https://doi.org/10.3389/fphar.2025.1652203}
}

RIS

TY  - JOUR
TI  - Prescription of EPs 7630 is associated with short- and long-term benefits in acute bronchitis: a real-world data analysis
AU  - Adrian Gillissen
AU  - Thorsten Reineke
AU  - Martin Burkart
AU  - Petra Funk
AU  - Charles Christian Adarkwah
AU  - Karel Kostev
PY  - 2025
JO  - Frontiers in Pharmacology
DO  - 10.3389/fphar.2025.1652203
UR  - https://doi.org/10.3389/fphar.2025.1652203
ER  - 

APA

Gillissen, A., Reineke, T., Burkart, M., Funk, P., Adarkwah, C. C., & Kostev, K. (2025). Prescription of EPs 7630 is associated with short- and long-term benefits in acute bronchitis: a real-world data analysis. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2025.1652203

Source records